CTI at the American Transplant Congress (ATC) 2026

CTI at the American Transplant Congress (ATC) 2026

The American Transplant Congress (ATC) brings together global leaders advancing one of the most clinically complex and tightly coordinated areas of clinical research. As transplant programs continue to evolve across solid organ, tissue, and immune-mediated conditions, sponsors face increasing scientific, regulatory, and operational expectations that require deep expertise and precision execution.

CTI is proud to attend ATC 2026, taking place June 20-24 in Boston, and remains committed to supporting transplant and immunology programs through thoughtful study design, cross-stakeholder coordination, and patient-centered execution.

What We're Focused on at ATC

CTI's teams are prepared to engage in conversations centered on practical, experience-backed approaches to transplant clinical development, including:

Advancing Transplant Clinical Development

• Trial design considerations across kidney, liver, heart, lung, pancreas, and composite tissue transplantation
• Managing immunosuppression, rejection, and immune-mediated safety profiles
• Endpoint selection and data strategies aligned with evolving standards of care
• Integrating real-world clinical practice into protocol development

Operational Execution in a Highly Specialized Environment

• Collaborating with academic research centers and investigator-led networks
• Global site activation and enrollment strategies for rare and complex populations
• Coordinating complex biomarker sampling and laboratory logistics
• Supporting long-term follow-up and post-approval research requirements

These discussions directly inform how CTI designs and executes trials that are scientifically rigorous, operationally efficient, and centered on patient outcomes.

Why Sponsors Choose CTI

For decades, CTI has partnered with sponsors developing therapies across transplantation, immunology, and rare diseases. Our approach combines senior scientific leadership with close collaboration across investigators, sites, and sponsors to help navigate complexity without unnecessary disruption.

Sponsors rely on CTI for:

• Deep transplant and immunology experience, informed by real-world clinical practice
• Senior, hands-on scientific and operational leadership across all study phases
• Global execution capabilities supporting complex site and laboratory coordination
• Regulatory and data strategies designed to anticipate challenges and reduce delays

Connect with CTI at ATC 2026

CTI looks forward to connecting with colleagues, partners, and new collaborators at ATC 2026. Members of our leadership and business development teams will be available to meet with sponsors focused on transplant and immune-mediated programs.

• Tim Schroeder, CEO & Chairman
• Dr. Helio Tedesco, Senior Medical Director
• Zach Sparks, Executive Director, Business Development & Client Management
• Earl Seltzer, Executive Director, Therapeutic Strategy & Innovation
• Katie Stanley, Senior Director, Business Development & Client Management

Reach out to schedule time with our team and learn how CTI can support transplant clinical development from early planning through long-term follow-up.